



**ASCO Direct**<sup>™</sup>  
**GU Highlights**  
**Meeting 2026**

# INVITATION

Friday, March 6, 2026 | 16:00 - 19:30 h  
Gleisarena FFHS Zürich and virtual

Update in Genitourinary Cancers

Registration:  
<https://events.springermedicine.com/asco-direct-gu-highlights-switzerland>

# PROGRAM

Friday, March 6, 2026 | 16:00 – 19:30h

16:00 – 16:05 **Introduction**  
*Aurelius Omlin, Arnold Templeton*

16:05 – 17:00

**Renal Cell Carcinoma**  
*Berna Özdemir, Ursula Vogl*

**Adjuvant treatment and the role of biomarkers in clear cell RCC**

LBA418

Adjuvant pembrolizumab plus belzutifan versus pembrolizumab for clear cell renal cell carcinoma (ccRCC): The randomized phase 3 LITESPARK-022 study.

Abstract 537

Circulating KIM-1 and ctDNA as prognostic markers in oligometastatic clear cell renal cell carcinoma (ccRCC): The K-COMPASS model.

**Sequencing metastatic clear cell and non-clear cell RCC overview**

LBA417

Belzutifan (bel) plus lenvatinib (lenva) versus cabozantinib (cabo) for advanced renal cell carcinoma (RCC) after anti-PD-(L)1 therapy: Open-label phase 3 LITESPARK-011 study.

Abstract 416

CYTOSHRINK: A randomized phase II trial of cytoreductive stereotactic hypofractionated radiotherapy with ipilimumab/nivolumab for metastatic kidney cancer.

Abstract 422

Fruquintinib plus serplulimab as first-line therapy in metastatic or unresectable non-clear cell renal cell carcinoma (nccRCC): Updated efficacy and safety data from a multicenter, single-arm, phase II trial.

17:15 – 18:15

**Urothelial Carcinoma and Testicular Cancer**  
*Arnold Templeton, Richard Cathomas, Christian Fankhauser*

**Testis Cancer: miRNA**

Abstract 586

Initial results from CLIMATE, a prospective cohort study assessing the clinical utility of miR-371a-3p (miR-371) as a marker of minimal residual disease (MRD) in clinical stage 1 testicular germ cell tumour (TGCT): ANZUP 1906.

**Bladder Cancer: MIBC**

Abstract 638

Pathological outcomes and disease-free survival (DFS) in KEYNOTE-905: Neoadjuvant and adjuvant (neoadj-adj) enfortumab vedotin (EV) plus pembrolizumab (pembro) in participants (pts) with muscle-invasive bladder cancer (MIBC) who are cisplatin-ineligible.

LBA630

Neoadjuvant and adjuvant enfortumab vedotin (EV) plus pembrolizumab (pembro) for participants with muscle-invasive bladder cancer (MIBC) who are eligible for cisplatin: Randomized, open-label, phase 3 KEYNOTE-B15 study.

**Bladder Cancer: NMIBC**

LBA629

SWOG S1602: A phase III randomized trial to evaluate BCG strain differences and priming with intradermal BCG before intravesical therapy for BCG-naïve high-grade non-muscle invasive bladder cancer (NCT #03091660).

18:15 – 18:45 **Apéro**

18:45 – 19:30

### Prostate Cancer

*Aurelius Omlin, Thomas Hermanns, Alexandros Papachristoflou*

#### Localised Prostate Cancer

##### LBA307

Androgen deprivation therapy and radiotherapy with or without cabazitaxel in very-high risk localized prostate cancer: First results of the PEACE-2 randomized phase III trial.

##### Abstract 308

External validation of a digital pathology-based multimodal artificial intelligence (MMAI)-derived prognostic biomarker in the randomised phase III CHHiP trial.

##### Abstract 305

Hormone therapy use and duration with post-operative radiotherapy for recurrent prostate cancer: An individual patient data meta-analysis.

#### Advanced Prostate Cancer

#### mHSPC - Quality of Life Data

##### Abstract 14

Patient reported outcomes (PRO) and tolerability of capivasertib (capi) plus abiraterone (abi) versus placebo (pbo) plus abi in patients (pts) with PTEN-deficient metastatic hormone-sensitive prostate cancer (mHSPC): CAPItello-281.

##### Abstract 18

Health-related quality of life, pain, and symptomatic skeletal events in the phase 3 PSMAddition study of [<sup>177</sup>Lu]Lu-PSMA-617 (<sup>177</sup>Lu-PSMA-617) combined with ADT and ARPI in patients with PSMA-positive mHSPC.

#### mCRPC - OS Data

##### Abstract 15

Final overall survival results from the EORTC 1333/PEACE-3 trial: Enzalutamide with or without radium-223 in metastatic castration-resistant prostate cancer.

##### Abstract 16

Overall survival from the phase 2 trial of abiraterone, olaparib, or abiraterone + olaparib in first-line metastatic castration-resistant prostate cancer (mCRPC) with DNA repair defects (BRCAAway).

19:25 – 19:30

#### Closing remarks

*Aurelius Omlin, Arnoud Templeton*

Please note that the agenda may be subject to change

Dear colleagues,

We are delighted to invite you to the annual **ASCO Direct™ GU Highlights Meeting 2026 on Friday, March 6, 2026**, at Gleisarena FFHS in Zurich.

The event will be chaired by **Aurelius Omlin** and **Arnaud Templeton** and will feature **highlights from the 2026 ASCO Genitourinary Cancers Symposium in San Francisco**. Leading Swiss experts will review the most important new data in **prostate, renal cell, and urothelial carcinoma**, and discuss their clinical relevance for our daily practice in Switzerland. The focus will be on translating the latest scientific findings into patient-oriented strategies, addressing current treatment challenges, and exploring the impact of emerging therapies on our GU oncology landscape.

We invite you to join us for this engaging and practice-oriented symposium, followed by an aperitif that provides an excellent opportunity for networking and exchange among colleagues.

We look forward to welcoming you!

Your chairs,



**PD Dr. med.  
Aurelius Omlin**  
Medical Oncologist  
Onkozentrum Zürich



**Prof. Dr. med.  
Arnaud Templeton**  
Medical Oncologist  
Claraspital Basel

Main Sponsor

**Johnson & Johnson**

Co-Sponsors



## Speakers

**Prof. Dr. med. Richard Cathomas**  
Kantonsspital Graubünden

**Prof. Dr. med. Christian Fankhauser**  
Kantonsspital Winterthur

**PD Dr. med. Thomas Hermanns**  
Hirslanden Zürich

**PD Dr. med. et phil. Berna Özdemir**  
Inselspital Bern

**Dr. med. Alexandros Papachristofilou**  
Universitätsspital Basel

**PD Dr. med. Ursula Vogl**  
Ente Ospedaliero Cantonale



Date: March 6, 2026  
16:00 - 19:30 h

Location: Gleisarena FFHS  
Zollstrasse 17  
8005 Zürich

Register now:



ASCO Direct™ is an officially licensed program of the American Society of Clinical Oncology®. ASCO® is a registered trademark of the American Society of Clinical Oncology. All rights reserved. ASCO® does not endorse any health care product, therapy, diagnostic test or device.